flow trial semaglutide kidney outcomes nejm 2024 hazard ratio ❇️Patients with obesity, type 2 #diabetes and chronic disease are at high risk for kidney failure, cardiovascular events, and death. This study, the now published, evaluated treatment with (# Kidney Outcomes With Glucagon-Like Peptide-1

For women whose hormonal shifts have disrupted their metabolic balance, GLP-1 therapy can act as a reset a way to restore equilibrium and re-engage the bodys natural systems of appetite and energy regulation

Wegovy has clinical studies showing specific weight loss percentages

Semaglutide, already approved by the FDA as a treatment for type 2 diabetes, is a synthetic version of the naturally occurring hormone GLP-1 and works on appetite centers in the brain and the gut, producing feelings of fullness

Understanding your genetic context in GLP-1 and glucose regulation pathways may help explain why your weight loss timeline differs from population averages

Cortisol and ACTH are hormones potentially involved in the stress response and are typically associated with various metabolic and immune actions